Navigation Links
Phase 2a Findings Demonstrate that CSL112, A Novel Apolipoprotein A-I Infusion Therapy, Has a Favorable Safety Profile, is Well Tolerated and Increases Cholesterol Efflux Capacity in Stable Atherothrombotic Patients
Date:11/20/2013

60;                                       

No treatment-emergent serious adverse events (AE) were reported during the active treatment period except for one case of atrial fibrillation which occurred in the placebo group.  Assessments of liver function and other key biochemical, hematologic and immunogenic measurements over time were similar across all CSL112 and placebo groups.

PK and PD analyses showed that CSL112 caused immediate and robust increases in apoA-I, the active component of high density lipoprotein (HDL). Blood levels of apoA-I rose in a dose-proportional fashion with elevations approaching three-fold baseline levels at the top dose.  The highly anti-atherosclerotic form of HDL known as PreBeta1 showed an even greater elevation, with increases up to 17-fold. CSL112 also enhanced key biomarkers of the early steps of reverse cholesterol transport with strong elevations in cholesterol efflux capacity observed across all CSL112 regimens.  Changes were maintained for up to 72 hours after infusion of CSL112 at the higher doses.

Potential antiplatelet effects of CSL112 were also evaluated in this population of patients who were receiving chronic dual antiplatelet therapy.  CSL112 did not significantly influence platelet aggregation in response to AA, ADP and collagen. Based on these data, it is anticipated that CSL112 will not affect hemostasis when administered with concomitant antiplatelet therapies.

"Patients who experience an ACS event have a great unmet need to reduce the risk of suffering another heart attack, stroke or other cardiovascular event, particularly within the first 30 days," said Chuck Shear, CSL Cardiovascular Therapeutic Area Head. "The results of this third clinical stu
'/>"/>

SOURCE CSL Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Commences Phase 2 Clinical Trial of XAF5 Gel to Reduce Submental Fat
2. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Surprise: Viruses Can Cause Disease during Latent Phase; New Evidence Supports Microcompetition Theory
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
6. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
7. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
8. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
9. KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
10. Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma
11. Xencors XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells ... sugars that are able to enter fat cells, inhibiting the formation of new ...
(Date:7/29/2015)... ... 29, 2015 , ... Costello served as Lead Levee Design Engineering Manager for ... County, Texas area from future storm surge flooding, such as occurred in Hurricane Ike ... alignment alternatives for providing protection, Costello also balanced socio-economic and environmental needs ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... (BI) advanced cell culture products, announces the availability of BI’s line of human ... Biological Industries, these stem cell differentiation media offer a complete system for multipotency ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... the company is making good progress in evaluating the full range of capabilities ... stem cells. Adult tissue stem cells perform the day-to-day renewal and repair of ...
Breaking Biology Technology:Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Preventing Storm Surge Flooding in Houston 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... N.J., March 14 Quest Diagnostics,Incorporated (NYSE: ... information and services, announced that it is scheduled ... Annual Health Care Conference on,Tuesday, March 18, 2008, ... Diagnostics presentation is scheduled to begin at,8:45 a.m. ...
... NuVasive, Inc. (Nasdaq:,NUVA), a medical device company focused on ... announced today,that Kevin O,Boyle, Executive Vice President and Chief ... Eleventh Annual Global,Healthcare Conference at the Loews Miami Beach ... at 10:15 a.m. ET., A live Web cast ...
... Bionovo, Inc.,(Nasdaq: BNVI ) announced today ... of Directors. Mr. Drapeau has extensive financial,management experience ... are quite excited to have access to Lou,s ... "Lou is particularly well versed,in the unique financial ...
Cached Biology Technology:Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3Louis Drapeau Joins Bionovo's Board of Directors 2Louis Drapeau Joins Bionovo's Board of Directors 3
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... Research Resources (NCRR), part of the National Institutes ... to an estimated $122 million over the next ... Networks of Biomedical Research Excellence (INBRE) in seven ... sharing of research resources and expertise, these awards ...
... sun bore down on a Honduran naval boat as it ... one of Central Americas most important seaports. Aboard the ... out at the distant horizon with some hint of concern ... up and the last few readings were definitely off. ...
... preferred by consumers, many growers use chemical "regulators" ... use of chemical growth retardants is standard practice ... chemicals are used to reduce plants, internode length, ... create aesthetically pleasing, spherical plants with plentiful flower ...
Cached Biology News:NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3Searching for pollution in the Caribbean 2Searching for pollution in the Caribbean 3Searching for pollution in the Caribbean 4Searching for pollution in the Caribbean 5Searching for pollution in the Caribbean 6Searching for pollution in the Caribbean 7Searching for pollution in the Caribbean 8Photoselective film proves effective for controlling height in potted gardenia plants 2
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
...
Biology Products: